Unpacking Key Data from ASH 2024 - Episode 6
Future of Bispecifics and CAR T in R/R MM
Panelists discuss how the preliminary results from the IMMagine-1 trial (ASH 2024, abstract #1031) on anitocabtagene autoleucel highlight the evolving role of bispecifics and chimeric antigen receptor (CAR) T-cell therapies in the treatment landscape for relapsed/refractory multiple myeloma (R/R MM).
Video Player is loading.
Video content above is prompted by the following:
Future of Bispecifics and CAR T in R/R MM:
The treatment landscape for R/R MM is evolving, with CAR T therapies and bispecific antibodies emerging as key modalities:
- CAR T Therapy: Anitocabtagene autoleucel adds to the growing body of evidence supporting personalized, deep, and durable responses in R/R MM, although accessibility and manufacturing time remain challenges.
- Bispecific Antibodies: Off-the-shelf alternatives offer flexibility and repeated dosing advantages, with ongoing trials optimizing sequencing and combination strategies.
Future research will focus on sequencing, combination approaches, and bridging strategies to enhance outcomes and accessibility in R/R MM treatment.
Related Content:
